Metastatic Colorectal CancerNCT01693835
"Cancersensor": Circadian Rhythms
An observational study of Metastatic Colorectal Cancer, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.
Trial summary
Observational, non randomized study aimed at measuring the circadian rhythms in the urinary concentrations of physiological modified nucleosides in 30 patients with metastatic colorectal cancer and in 30 age and sex-matched healthy subjects. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Metastatic Colorectal Cancer
- How many people
- 32 participants
- Where
- 1 siteFrance
- Study dates
- Aug 2012to Jun 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients with metastatic colorectal cancer treated at the Department of Medical Oncology of Paul Brousse Hospital
Who may be able to join
- Histologically-confirmed metastatic colorectal cancer;
- 0 to 3 prior chemotherapy lines;
- Signed informed consent;
- Good understanding of the protocol and of the follow-up;
- Estimated life expectancy exceeding 3 months;
- At least one measurable metastatic lesion (RECIST criteria);
Show all 14Show fewer
- Performance Status (WHO) of 0 to 2;
- Good haematological, hepatic and renal functions.
- Age ≥ 18 ans
- Signed informed consent;
- Good understanding of the protocol and of the follow-up;
- Good haematological, hepatic and renal functions.
- Test HIV and B and C hepatitis negative test
- No chronic or acute diseases
Who cannot join
- Poor performance status (>2);
- Poor haematological, hepatic or renal functions;
- Uncontrolled chronic disease;
- Serious unhealed wound, ulcer or fracture within the previous month;
- Clinical or laboratory finding suggesting possible abnormalities in nucleosides urinary excretion;
- Pregnancy or breast-feeding during the previous month;
Show all 15Show fewer
- Transmeridian trip of more than 4 time zones within the prior 2 weeks;
- Person with legal restriction to participate into clinical research, according to the current law in France.
- Poor haematological, hepatic or renal functions;
- Uncontrolled chronic disease;
- Serious unhealed wound, ulcer or fracture within the previous month;
- Clinical or laboratory finding suggesting possible abnormalities in nucleosides urinary excretion;
- Pregnancy or breast-feeding during the previous month;
- Transmeridian trip of more than 4 time zones within the prior 2 weeks;
- Person with legal restriction to participate into clinical research, according to the current law in France.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Molecularly Imprinted Polymer Sensors of Modified Nucleosides for Non-invasive Monitoring of Cancer Therapy : the Circadian Rhythms of Urinary Excretion of Modified Nucleosides.
Observational, non randomized study aimed at measuring the circadian rhythms in the urinary concentrations of physiological modified nucleosides in 30 patients with metastatic colorectal cancer and in 30 age and sex-matched healthy subjects.
- Conditions
- Metastatic Colorectal Cancer
- Keywords
- Colorectal, Cancer, Metastatic, Healthy, Control, Circadian, Urine, Nucleosides
- Medical subject headings
- Colorectal Neoplasms, Neoplasms, Neoplasm Metastasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients | Patients with metastatic colorectal cancer | |
| Healthy subjects | Age and sec-matched healthy subjects |
What is being measured
The primary outcome is the main question the study is designed to answer.
Circadian rhythms in urinary excretion of modified nucleosides
10 Urine samples over 2 days Measurement of modified nucleosides, cortisol and 6-sulfatoxymelatonin concentration
1 saliva sample Measurement of Clock genes polymorphisms expression
Measured: 2 days repeated measures
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Sep 2012 (estimated)
- Study startAug 2012
- Primary completionJun 2014
- Study completionJun 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Metastatic Colorectal CancerStudies of the same condition, open and under way.
- More trials run by Institut National de la Santé Et de la Recherche Médicale, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Francis Lévi, MD, PhD, Principal investigator, INSERM and AP-HP and Paris South UniversitySandrine Dulong, PhD, Study director, Institut National de la Santé Et de la Recherche Médicale, France
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01693835
- Sponsor's protocol ID
- C11-42
- Other IDs
- 2012-A00010-43
- Status last verified
- Dec 2016
- First submitted
- 7 Sep 2012
- Last updated
- 18 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
Publications
Dulong S, Huang Q, Innominato PF, Karaboue A, Bouchahda M, Pruvost A, Theodoro F, Agrofoglio LA, Adam R, Finkenstadt B, Levi F. Circadian and chemotherapy-related changes in urinary modified nucleosides excretion in patients with metastatic colorectal cancer. Sci Rep. 2021 Dec 14;11(1):24015. doi: 10.1038/s41598-021-03247-2.
PubMed 34907230
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Molecularly Imprinted Polymer Sensors of Modified Nucleosides for Non-invasive Monitoring of Cancer Therapy : the Circadian Rhythms of Urinary Excretion of Modified Nucleosides.
- ClinicalTrials.gov ID
- NCT01693835
- Acronym / sponsor ID
- C11-42
- Conditions
- Metastatic Colorectal Cancer
- Keywords
- Colorectal, Cancer, Metastatic, Healthy, Control, Circadian, Urine, Nucleosides
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- Institut National de la Santé Et de la Recherche Médicale, FranceOther government
- Study start
- Aug 2012
- Primary completion
- Jun 2014 (actual)
- Study completion
- Jun 2014 (actual)
- First posted
- 26 Sep 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Observational, non randomized study aimed at measuring the circadian rhythms in the urinary concentrations of physiological modified nucleosides in 30 patients with metastatic colorectal cancer and in 30 age and sex-matched healthy subjects.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients | – | –Patients with metastatic colorectal cancer |
| Healthy subjects | – | –Age and sec-matched healthy subjects |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with metastatic colorectal cancer treated at the Department of Medical Oncology of Paul Brousse Hospital
Key inclusion criteria (14 listed)
- Histologically-confirmed metastatic colorectal cancer;
- 0 to 3 prior chemotherapy lines;
- Signed informed consent;
- Good understanding of the protocol and of the follow-up;
- Estimated life expectancy exceeding 3 months;
Key exclusion criteria (15 listed)
- Poor performance status (>2);
- Poor haematological, hepatic or renal functions;
- Uncontrolled chronic disease;
- Serious unhealed wound, ulcer or fracture within the previous month;
- Clinical or laboratory finding suggesting possible abnormalities in nucleosides urinary excretion;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Circadian rhythms in urinary excretion of modified nucleosides
Time frame: 2 days repeated measures
10 Urine samples over 2 days Measurement of modified nucleosides, cortisol and 6-sulfatoxymelatonin concentration 1 saliva sample Measurement of Clock genes polymorphisms expression
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2025.
- Results publication: PubMed 34907230Dulong S, Huang Q, Innominato PF, Karaboue A, Bouchahda M, Pruvost A, Theodoro F, Agrofoglio LA, Adam R, Finkenstadt B, Levi F. Circadian and chemotherapy-related changes in urinary modified nucleosides excretion in patients with metastatic colorectal cancer. Sci Rep. 2021 Dec 14;11(1):24015. doi: 10.1038/s41598-021-03247-2.
Related trials for Metastatic Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study
Colorectal Cancer (CRC)
Not yet recruiting
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
Not yet recruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
RecruitingPhase 2
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Francis Lévi, MD, PhD principal investigator
INSERM and AP-HP and Paris South University
Sandrine Dulong, PhD study director
Institut National de la Santé Et de la Recherche Médicale, France
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Metastatic Colorectal Cancer, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Circadian rhythms in urinary excretion of modified nucleosides (time frame: 2 days repeated measures). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01693835, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2025.